A Study of PTS for Patients With Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03448211
• Other study ID #: US-01
• Status: Withdrawn
• Phase: Phase 1
• First received: February 6, 2018
• Last updated: April 3, 2018
• Start date: May 1, 2018
• Est. completion date: August 1, 2019

Study information

• Verified date: April 2018
• Source: PTS International Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the MTD of PTS following local and intratumoral injections over a treatment course of two 5-day cycles to patients with palpable advanced solid malignancies who have failed standard treatment.

Description:

The study will be an open, uncontrolled, single-center, phase I study to assess the safety and tolerability of local intra-tumoral injection 2.0ml (660mg), 4.0ml (1220mg), 6.0ml (1880mg) and 8.0ml (2440mg) PTS in female breast cancer patients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 1, 2019
• Est. primary completion date: May 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects are diagnosed as unsuitable for surgical operations or refuse to do so.

• Subject's performance status is classified as Grade 0 to Grade 3. Estimated survival time should be longer than 6 months of time.

• Physical examinations show no serious functional disorders of the heart, liver, kidneys, or blood.

• Subjects were treated with radio or chemotherapy previously. A minimum of 2 to 3 months recovery time is required before treating with this investigational drug.

• Subject is diagnosed as intratracheal lesions with metastasized pulmonary cancer not suitable for surgery, or refuses to be operated.

• Subject should show lobular atelectasis with either complete or incomplete obstruction of the bronchi.

• Physical examinations should show no functional disorders of the heart, liver, kidneys, central nervous system, and blood.

• Subject performance status to be classified from Grade 0 to Grade 3, who can tolerate the fiberoptic bronchoscopy treatments.

• In-patient is preferred. When subject is in satisfactory conditions, the out Cpatient can also be enrolled in this trial.

• Two to three months recovery time is required for the subject has just received radio or chemotherapy.

• Emergency request, subjects with serious lobular atelectasis and almost complete obstruction of the bronchi.

• With the aid of a tracheal intubation and the help of the respirator, PTS may be intraumorally injected into the obstructed lesion via fiberoptic bronchoscopy outside of the tube, alongside of the intubation.

Exclusion Criteria:

• Pregnant women and children will not be used as test subjects.

• Subjects with serious functional disorders of the heart, liver, kidneys, or blood will be excluded.

• Subjects who do not want to participate in the trial will not be used as test subjects.

• Subject does not agree to participate.

• Subject performance status is Grade 4, and the one who does not want to tolerate the discomfort of the PTS treatments via fiberoptic bronchscopy.

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• Para-toluenesulfonamide Injection (PTS)
Intratumoral injection

Locations

Country	Name	City	State
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
PTS International Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerable dose	Maximum tolerable dose	4 weeks post-treatment